Research programme: CNS disorder therapeutics - Taisho/Merck

Drug Profile

Research programme: CNS disorder therapeutics - Taisho/Merck

Alternative Names: MGS 0008; MGS 0028; MGS 0210

Latest Information Update: 23 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer Merck & Co; Taisho Pharmaceutical
  • Class Dicarboxylic acids
  • Mechanism of Action Metabotropic glutamate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 31 Oct 2006 Preclinical trials in Anxiety disorders in Japan (Intraperitoneal)
  • 31 Oct 2006 Preclinical trials in Depression in Japan (Intraperitoneal, PO)
  • 31 Oct 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Affective Disorders and Anxiety Disorders pharmacodynamics sections and the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top